Pharmapedia

The proposed India-European Union (EU) trade deal is expected to bring significant benefits to India’s pharmaceutical industry. The EU is one of the largest and most regulated medicine markets in the world, and easier access to this region can open new growth opportunities for Indian drug manufacturers. The agreement focuses not only on trade but also on regulatory cooperation, which is crucial for pharmaceuticals.

Mounjaro (tirzepatide) has emerged as one of the most impactful brands in the GLP‑1 category, showing remarkable traction over the last nine months. With growing acceptance among clinicians and increasing awareness among patients, Mounjaro’s performance reflects both strong clinical confidence and rising demand in the metabolic therapy space.

Researchers at Washington University School of Medicine in St. Louis suggest that common stimulant medications used to treat attention-deficit/hyperactivity disorder (ADHD), such as Ritalin and Adderall, may work in ways scientists didn’t previously understand. The findings challenge the long-held belief that these drugs primarily improve attention by acting directly on the brain’s attention circuits.

In global pharmaceuticals, credibility is no longer conferred by capacity alone. It is earned— slowly, visibly, and irreversibly—through regulatory trust. As drug supply chains fragment, re- regionalize, and digitize, the decisive question for India’s pharmaceutical future is no longer how much we manufacture, but how seamlessly our regulatory systems align with the world we serve.